Product Information
NEVIRAPINE ER 400 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $1.5719 per EA under NDC 33342023807. Its NADAC has been published 287 times since Aug 8, 2018.
FDA first approved this application on Oct 6, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342023807
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NEVIRAPINEApproval Type
Generic (ANDA)
FDA Application
ANDA206879FDA Approved
10/6/2017
TE Code
AB
On Market Since
10/7/2017
Pharmacological Classes
Price Statistics
The NADAC for NEVIRAPINE ER 400 MG TABLET has been published 287 times since Aug 8, 2018, and over the history we have for it it has declined 81.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5719 per EA |
|---|---|
| All-time high | $8.3108 (Aug 15, 2018) |
| All-time low | $1.2487 (Jan 21, 2026) |
| 52-week high | $1.7141 |
| 52-week low | $1.2487 |
| Median price | $3.2679 |
| Average price | $3.2566 |
| Largest weekly change | -59.4% (Apr 17, 2024) |
| Weeks tracked | 287 |
| Tracking since | Aug 8, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the NEVIRAPINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
NEVIRAPINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NEVIRAPINE ER 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NEVIRAPINE ER 400 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $1.5719 per EA (NDC 33342023807), effective Sep 30, 2026.
How has the price of NEVIRAPINE ER 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for NEVIRAPINE ER 400 MG TABLET has declined 81.1%. It has been tracked across 287 weekly CMS publications since Aug 8, 2018.
What are the highest and lowest recorded NADAC prices for NEVIRAPINE ER 400 MG TABLET?
Since Aug 8, 2018, the NADAC for NEVIRAPINE ER 400 MG TABLET has ranged from a low of $1.2487 (Jan 21, 2026) to a high of $8.3108 (Aug 15, 2018), with a median of $3.2679 per EA.
Are there cheaper alternatives to NEVIRAPINE ER 400 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of NEVIRAPINE ER 400 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures NEVIRAPINE ER 400 MG TABLET?
NEVIRAPINE ER 400 MG TABLET (NDC 33342023807) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.